To mitigate the challenge of recurrent tumor cells expressing wild-type EGFR protein in EGFRvIII CAR-T-cell therapy, Choi et al. investigated in a first-in-human trial open-label study with three rGBM patients using the intraventricular application of an engineered T-cell product (CARv3-TEAM-E) that targets EGFRvIII through a second-generation CAR while also secreting T-cell-engaging antibody molecules (TEAMs) against wild-type EGFR, which is not expressed in the normal brain but is nearly always expressed in glioblastoma [24]. The gene discussed is EGFR; the disease is neoplasm.